Skip to Content

Notice

Fibromyalgia Public Meeting on Patient-Focused Drug Development; Correction

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice of public meeting; request for comments; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a document that appeared in the Federal Register of September 23, 2013 (78 FR 58313). The document announced a public meeting entitled “Fibromyalgia Public Meeting on Patient-Focused Drug Development” and opportunity for public comment. The document published with an incorrect date for submission of electronic and written comments. This document corrects that error.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Graham Thompson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 1199, Silver Spring, MD 20993, 301-796-5003, FAX: 301-847-8443, email: graham.thompson@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In FR Doc 2013-23019, appearing on page 58313 Start Printed Page 63224in the Federal Register of Monday, September 23, 2013, the following corrections are made:

1. On page 58313, in the first column, in the “Dates” section, the last sentence is corrected to read “Submit electronic or written comments by February 10, 2014.”

2. On page 58314, in the second column, in the fourth full paragraph, the last sentence is corrected to read “Comments may be submitted until February 10, 2014.”

Start Signature

Dated: October 3, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2013-24782 Filed 10-22-13; 8:45 am]

BILLING CODE 4160-01-P